Key result
Angiotensin II increases superoxide production ~73% in human internal mammary arteries vs control.
Why the study?
Increased vascular superoxide anion production contributes to endothelial dysfunction and hypertension, but the sources and mechanisms in human blood vessels are unclear.
Angiotensin II increases superoxide production in human internal mammary arteries via an AT1 receptor-dependent mechanism involving NAD(P)H oxidase.
Answers are grounded in this paper and cite their sources.
May increase vascular oxidative stress via AT1/NAD(P)H oxidase in models; leaves open clinical relevance to human endothelial dysfunction.
BACKGROUND: Increased vascular superoxide anion (.O(2)(-)) production contributes to endothelial dysfunction and hypertension in animal models of cardiovascular disease. Observations in experimental animals suggest that angiotensin II (Ang II) increases.O(2)(-) production by activation of vascular NAD(P)H oxidase. We studied the sources of.O(2)(-) production in human blood vessels and investigated whether, and by what mechanism, Ang II might alter vascular.O(2)(-) production. METHODS AND RESULTS: Internal mammary arteries (IMAs) and saphenous veins (SVs) were collected at the time of cardiac surgery. Vessels were incubated in Krebs buffer at 37 degrees C.O(2)(-) was measured by lucigenin chemiluminescence. Basal. O(2)(-) concentrations were greater in IMAs than SVs. Inhibitors of NAD(P)H oxidase (10 micromol/L to 200 micromol/L diphenyleneiodonium) and xanthine oxidase (1 mmol/L allopurinol) caused reductions in.O(2)(-) concentrations in both IMAs and SVs. Western blotting of superoxide dismutase proteins demonstrated similar expression in IMAs and SVs. Vessels were also incubated in the presence or absence of Ang II (1 pmol/L to 1 micromol/L). Ang II increased.O(2)(-) production in IMAs at 4 hours of incubation (control, 978+/-117 pmol. min(-1). mg(-1); 1 micromol/L of Ang II, 1690+/-213 pmol. min(-1). mg(-1); n=27, P=0.0001, 95% CI 336, 925) but not in SVs. This effect was completely inhibited by coincubation of IMAs with DPI (100 micromol/L), a nonspecific Ang II antagonist ([sar(1), thre(8)]-Ang II, 1 micromol/L) and a specific Ang II type 1 (AT(1)) receptor antagonist (losartan, 1 micromol/L). Conclusions-. O(2)(-) production is greater in human IMAs than in SVs. NAD(P)H oxidase and xanthine oxidase are sources of.O(2)(-) production in these vessels. The vasoactive peptide Ang II increases.O(2)(-) production in human arteries by an AT(1) receptor-dependent mechanism.
No takes yet. Share an insight, caveat, or question.
Berry et al. (2000) studied Cardiovascular disease (patients undergoing cardiac surgery) (n=27). Angiotensin II vs. Control (absence of Angiotensin II) was evaluated on Superoxide production in internal mammary arteries (95% CI 336, 925, p=0.0001). Angiotensin II increased superoxide production in human internal mammary arteries compared to control.
Synapse has enriched 10 related papers. Consider them for comparative context: